Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 11, 2026 | June 15, 2026 |
| Fortrea Holdings Inc.FTRE · Entity 4623 | Director | August 03, 2026 | August 05, 2026 |
| Novan, Inc.NOVN · Entity 111882 | Director | June 27, 2023 | June 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,936 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,294 · Balance 45,936 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $8.50 · Expires 2036-06-11 | Direct | 33,540 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 33,540 · Balance 33,540 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Fortrea Holdings Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,399 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Sale · Disposed 9,700 · Balance 36,399 F1: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person. F2: This number reflects the aggregate amount of Common Stock held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person.
F2: This number reflects the aggregate amount of Common Stock held by the reporting person.
Novan, Inc.
Report date June 27, 2023 · Filed June 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,248 |
Reported balance
After 2023-06-27 transaction · row 1
1 source rowRow 1 · 2023-06-27 · Sale · Disposed 11,553 · Balance 25,248 F1: The reported shares were sold to satisfy tax obligations of the Reporting Person incurred upon the vesting and settlement of certain restricted stock units that vested on June 7, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy tax obligations of the Reporting Person incurred upon the vesting and settlement of certain restricted stock units that vested on June 7, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Radius Health, Inc.
Report date August 15, 2022 · Filed August 15, 2022
Section 16 reporting ended · disclosed 2022-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-15 transaction · row 1
1 source rowRow 1 · 2022-08-15 · Disposition to issuer · Disposed 5,500 · Balance 0 F1: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2032-01-14 | Direct | 0 |
Reported balance
After 2022-08-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share.
F2: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 20:04 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | SaleCommon Stock | 9,700 | $18.01 | $174,697.00 |
DisclosureSEC source: 0001965040-26-000111 · form4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,399 F1 · security: The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 33,540 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0000882796-26-000043 · form4.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,540 Underlying: Common Stock · 33,540 shares Expires 2036-06-11 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 15,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-26-000043 · form4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,936 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:18 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 12,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000086 · form4.xml · derivative · entry 3 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,852 Underlying: Common Stock · 12,852 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F5 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service as a director. F5 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service as a director. F6 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:18 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000086 · form4.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F3 · derivative.exercise_date: Represents an RSU award that vested in its entirety on June 10, 2026. F3 · derivative.expiration_date: Represents an RSU award that vested in its entirety on June 10, 2026. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:18 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000086 · form4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 9,600 | $7.14 | $68,544.00 |
DisclosureSEC source: 0000882796-25-000017 · form4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,642 F1 · shares: These shares were sold pursuant to a plan adopted by the Reporting Person on August 14, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale occurred automatically and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 27,181 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001171843-25-003918 · ownership.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,181 Underlying: Common Stock · 27,181 shares Expires 2035-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003918 · ownership.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,242 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:18 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017404 · form4.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,817 Underlying: Common Stock · 38,817 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2025, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after June 10, 2025, subject to the Reporting Person's continued service as a director. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:45 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014734 · form4.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F3 · derivative.exercise_date: Represents an RSU award that vested in its entirety on May 14, 2025. F3 · derivative.expiration_date: Represents an RSU award that vested in its entirety on May 14, 2025. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:45 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014734 · form4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| June 17, 2024 Filed Jun 17, 2024 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 4,689 | $6.00 | $28,134.00 |
DisclosureSEC source: 0001127602-24-018846 · form4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,742 F1 · shares: These shares were sold with the sole purpose of generating sufficient proceeds to cover the tax liability incurred in connection with the vesting of 16,745 Restricted Stock Units on June 13, 2024. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.99 to $6.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 49,933 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001127602-24-018737 · form4.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 6,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018737 · form4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,431 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:40 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015696 · form4.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,282 Underlying: Common Stock · 7,282 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after May 14, 2024, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after May 14, 2024, subject to the Reporting Person's continued service as a director. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 22:30 UTC | Novan, Inc. NOVN · Entity 111882 | SaleCommon Stock | 11,553 | $0.41 | $4,715.93 |
DisclosureSEC source: 0001467154-23-000073 · wf-form4_168790499279589.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,248 F1 · kind: The reported shares were sold to satisfy tax obligations of the Reporting Person incurred upon the vesting and settlement of certain restricted stock units that vested on June 7, 2023. Read SEC document |
| June 15, 2023 Filed Jun 15, 2023 20:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 4,000 | $7.98 | $31,920.00 |
DisclosureSEC source: 0001127602-23-018783 · form4.xml · nonDerivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,611 Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 39,072 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001127602-23-018783 · form4.xml · derivative · entry 3 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:37 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 16,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018783 · form4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,611 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 01:21 UTC | Novan, Inc. NOVN · Entity 111882 | Exercise / conversionRestricted Stock Units · Derivative | 36,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001467154-23-000063 · wf-form4_168627370772603.xml · derivative · entry 3 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,101 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs fully vested on June 7, 2023. F4 · derivative.expiration_date: The RSUs fully vested on June 7, 2023. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 01:21 UTC | Novan, Inc. NOVN · Entity 111882 | Exercise / conversionCommon Stock | 36,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001467154-23-000063 · wf-form4_168627370772603.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") on June 7, 2022. Each RSU represented a contingent right to receive one share of the Issuer's Common Stock. 36,101 RSUs fully vested on June 7, 2023 and were settled in shares of the Issuer's Common Stock. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:21 UTC | Novan, Inc. NOVN · Entity 111882 | GrantRestricted Stock Units · Derivative | 103,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001467154-23-000063 · wf-form4_168627370772603.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,092 Underlying: Common Stock · 103,092 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs shall be fully vested on the first anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service as of the vesting date. F3 · derivative.expiration_date: The RSUs shall be fully vested on the first anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service as of the vesting date. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 20:19 UTC | Radius Health, Inc. RDUS · Entity 124173 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | $3.60 Strike: $6.40 | $36,000.00 |
DisclosureSEC source: 0000899243-22-028647 · doc4.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-01-14 F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 20:19 UTC | Radius Health, Inc. RDUS · Entity 124173 | Disposition to issuerCommon Stock | 5,500 | $10.00 | $55,000.00 |
DisclosureSEC source: 0000899243-22-028647 · doc4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. F1 · price: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,022 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001127602-22-017169 · form4.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:53 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017169 · form4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,866 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:28 UTC | Novan, Inc. NOVN · Entity 111882 | GrantRestricted Stock Units · Derivative | 36,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001467154-22-000097 · wf-form4_165481007467241.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,101 Underlying: Common Stock · 36,101 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs") as the annual award made on the annual meeting date pursuant to the terms of the Issuer's Non-Employee Director Compensation Policy, and each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs shall be fully vested on the first anniversary of the grant date of such RSUs. F2 · derivative.expiration_date: The RSUs shall be fully vested on the first anniversary of the grant date of such RSUs. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 22:06 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantNon-Qualified Stock Option · Derivative | 26,667 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001171843-22-000942 · ownership.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 26,667 shares Expires 2032-02-08 F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan. F2 · derivative.exercise_date: The option vests 1/36 per month for a period of 36 months, beginning on March 8, 2022. Read SEC document |
| January 14, 2022 Filed Jan 25, 2022 21:31 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-22-004789 · doc4.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-14 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date. Read SEC document |
| January 14, 2022 Filed Jan 25, 2022 21:31 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004789 · doc4.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:57 UTC | Novan, Inc. NOVN · Entity 111882 | GrantStock Option (Right to Buy) · Derivative | 8,923 | $0.00 Strike: $9.19 | $0.00 |
DisclosureSEC source: 0001467154-21-000091 · wf-form4_162223545116836.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,923 Underlying: Common Stock · 8,923 shares Expires 2031-05-25 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on August 26, 2021. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:39 UTC | Novan, Inc. NOVN · Entity 111882 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001467154-21-000053 · wf-form4_162033353760459.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-05-03 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on August 4, 2021. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:34 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $18.17 | $0.00 |
DisclosureSEC source: 0001209191-21-001109 · doc4.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: This option shall vest in substantially equal installments on each of the first four anniversaries of January 4, 2021. Read SEC document |
| July 28, 2020 Filed Jul 31, 2020 01:14 UTC | Novan, Inc. NOVN · Entity 111882 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001467154-20-000120 · wf-form4_159615807796296.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-07-27 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on October 28, 2020. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:16 UTC | Novan, Inc. NOVN · Entity 111882 | PurchaseWarrant (Right to Buy) · Derivative | 7,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001467154-20-000028 · wf-form4_158344295414435.xml · derivative · entry 2 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2025-03-03 F3 · price: The combined price for each share of common stock (disclosed in Table I) and the accompanying warrant was $0.30. F2 · derivative.exercise_date: The warrants to purchase 7,000 shares of Common Stock of the Issuer may be exercised at any time prior to the expiration date. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:16 UTC | Novan, Inc. NOVN · Entity 111882 | PurchaseCommon Stock | 7,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001467154-20-000028 · wf-form4_158344295414435.xml · nonDerivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 F1 · price: The combined price for each share of common stock and the accompanying warrant (disclosed in Table II) was $0.30. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 20:18 UTC | Novan, Inc. NOVN · Entity 111882 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001467154-19-000061 · wf-form4_156477712170196.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-07-30 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on October 31, 2019. Read SEC document |
| June 04, 2018 Filed Jun 8, 2018 00:57 UTC | Novan, Inc. NOVN · Entity 111882 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-18-036556 · doc4.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-03 F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on September 4, 2018. Read SEC document |
| September 24, 2017 Filed Sep 26, 2017 22:15 UTC | Novan, Inc. NOVN · Entity 111882 | GrantStock Option (right to buy) · Derivative | 19,240 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001209191-17-054047 · doc4.xml · derivative · entry 1 SANDERS MACHELLE · CIK 0001718020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,240 Underlying: Common Stock · 19,240 shares Expires 2027-09-23 F1 · derivative.exercise_date: The option vests in four equal installments, with the first installment vesting on December 24, 2017 and subsequent installments vesting every three months thereafter, such that the option will be fully vested on September 24, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.